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Advanced-stage peritoneal carcinomatosis is resistant to current chemotherapy treatment and, in the case of
metastatic ovarian cancer, results in a devastating 15%–20% survival rate. Therapeutics that restore genes inactivated
during oncogenesis are predicted to be more potent and specific than current therapies. Experiments with viral vectors
have demonstrated the theoretical utility of expressing the p53 tumor suppressor gene in cancer cells. However,
clinically useful alternative approaches for introducing p53 activity into cancer cells are clearly needed. It has been
hypothesized that direct reactivation of endogenous p53 protein in cancer cells will be therapeutically beneficial, but
few tests of this hypothesis have been carried out in vivo. We report that a transducible D-isomer RI-TATp53C9 peptide
activates the p53 protein in cancer cells, but not normal cells. RI-TATp53C9 peptide treatment of preclinical terminal
peritoneal carcinomatosis and peritoneal lymphoma models results in significant increases in lifespan (greater than 6-
fold) and the generation of disease-free animals. These proof-of-concept observations show that specific activation of
endogenous p53 activity by a macromolecular agent is therapeutically effective in preclinical models of terminal
human malignancy. Our results suggest that TAT-mediated transduction may be a useful strategy for the therapeutic
delivery of large tumor suppressor molecules to malignant cells in vivo.
Introduction
Most patients who succumb to cancer do so not from
primary tumor burden, but from metastatic disease (Fidler
2003). For example, advanced-stage peritoneal carcinomato-
sis (e.g., from metastatic ovarian and breast cancer) and
disseminated peritoneal lymphomas are often resistant to
current chemotherapy treatment (Parsons et al. 1996).
Posttreatment survival rates for patients presenting with
metastatic ovarian peritoneal carcinomatosis or lymphoma
are less than 20% and less than 50%, respectively (Lam and
Zhao 1997; Deppe and Baumann 2000; Hofstra et al. 2000).
Consequently, the development of novel therapeutic strat-
egies to reverse these numbers is clearly warranted.
A signiﬁcant effort has been aimed at understanding the
function of tumor suppressor gene pathways that are
genetically and epigenetically altered during oncogenesis
(Macleod 2000). One rationale for the study of tumor
suppressor pathways is the hypothesis that reconstitution of
these pathways in cancer patients will be therapeutically
beneﬁcial (Macleod 2000). The p53 tumor suppressor protein
induces growth arrest and apoptosis in response to cellular
stress (Vousden and Lu 2002). Mutation of genes in the p53
pathway is thought to be nearly universal in human cancer
(Vousden and Lu 2002). Thus, any strategy designed to restore
p53 activity in tumor cells will likely be an effective means of
inducing cancer cell death and will be applicable to a large
fraction of cancer patients. The inability of large tumor
suppressor proteins, all of which are intracellular, to cross the
plasma membrane precludes the therapeutic administration
of recombinant tumor suppressors in a manner analogous to
administration of extracellular biological therapeutics (e.g.,
insulin or G-CSF). Thus, the development of an efﬁcient
methodology for restoring tumor suppressor function to
cancer cells in vivo remains a challenge for both basic and
clinical researchers.
Gene therapy approaches aimed at restoring tumor
suppressor function have been extensively investigated. Both
viral and nonviral vectors have been employed to express
exogenous tumor suppressor genes, such as p53, in cancer
cells (McCormick 2001). Although gene therapy may be useful
under certain conditions, problems associated with immuno-
genicity and lack of systemic biodistribution to disseminated
metastases are likely to curtail its anticancer efﬁcacy (Mc-
Cormick 2001).
Delivery of macromolecules by protein transduction has
recently emerged as an alternative methodology for directly
introducing tumor suppressor proteins into cancer cells in
vivo. Several small cationic peptides, including TAT, Antp,
and polyArg (referred to as protein transduction domains
[PTDs]), are capable of traversing the plasma membrane and
entering the cytoplasm of cells by a concentration-depend-
ent, but receptor-independent, macropinocytic mechanism
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(Wadia et al. 2004). PTDs have recently been used to deliver a
wide range of cargo, including biologically active proteins,
peptides, nucleic acids, and iron beads, into cells in culture
(Fischer et al. 2001; Lindsay 2002). PTDs have also been
employed to deliver biologically active cargo into most, if not
all, tissues in preclinical models (Schwarze et al. 1999).
Because of the presence of either wild-type or mutant p53
protein in most tumors, it has been hypothesized that
restoration of endogenous p53 activity in cancer cells will
be a therapeutically efﬁcacious alternative to delivery of
exogenous p53. However, this hypothesis has been tested in
vivo in only a limited number of cases (Foster et al. 1999;
Bykov et al. 2002) and has never been tested in preclinical
models of terminal human malignancy. We therefore focused
on a strategy to activate endogenous p53 in cancer cells by
PTD-mediated delivery. The C-terminus of p53 is a lysine-
rich domain that is subjected to a variety of posttranslational
modiﬁcations (Apella and Anderson 2001). A peptide derived
from the C-terminus was previously shown by D. Lane’s group
(University of Dundee, United Kingdom) to activate speciﬁc
DNA binding by p53 in vitro by an unknown mechanism
(Hupp et al. 1995). In cancer cells, p53C9 peptide can induce
apoptosis by activating wild-type p53 protein and by
restoring function to several p53 DNA contact mutants.
Importantly, the p53C9 peptide also restores speciﬁc DNA
binding to some p53 DNA contact mutants in vitro and
induces apoptosis in cancer cells expressing p53 DNA contact
mutants (Selivanova et al. 1997, 1998; Kim et al. 1999).
However, the peptide fails to induce apoptosis in p53-
deﬁcient tumor cells or in tumor cells containing p53
structural mutations. In contrast, primary cells are resistant
to p53C9 peptide action (Selivanova et al. 1997; Kim et al.
1999). This resistance is likely a result of the extremely low
levels of endogenous p53 present in normal cells and the
absence of continual DNA damage often associated with
tumor cells (Selivanova et al. 1997; Kim et al. 1999).
Here we report a proof-of-concept that in vivo delivery of a
transducible, proteolytically stable p53C9 peptide (termed RI-
TATp53C9) is a therapeutically effective means of activating
the p53 tumor suppressor pathway in preclinical models of
terminal metastatic cancer.
Results
Activation of p53 by Transducible Retro-Inverso D-Isomer
p53C9 Peptide
Although PTDs solve one major obstacle to the use of
intracellular peptides as therapeutics, the susceptibility of
peptides to degradation in vivo remains problematic. To
circumvent the problem of proteolytic degradation, we
synthesized a retro-inverso version of the parental p53C9
peptide by inverting the peptide sequence, using D-isomer
residues, and adding the TAT PTD to obtain a transducible
RI-TATp53C9 peptide (Figure 1A). This double inversion of
peptide structure often leaves the surface topology of the
sidechains intact and has been used extensively to stabilize
biologically active peptides for in vivo applications (Chorev
and Goodman 1993). Because of their greater stability, retro-
inverso peptides often display increased potency.
To determine whether the RI-TATp53C9 peptide retained
functionality, we compared the transducible parental L-
isomer p53C9TAT and D-isomer RI-TATp53C9 peptides for
the ability to induce a cell cycle arrest (Figure 1B). Treatment
of murine TA3/St mammary carcinoma cells (which express
wild-type p53) with either the L-isomer p53C9TAT or D-
isomer RI-TATp53C9 peptides resulted in a concentration-
dependent G1 cell cycle arrest (Figure 1B and 1C). The
control D-isomer mutant peptide had little to no effect
(Figure 1B and 1C). Compared to the L-isomer p53C9TAT,
the D-isomer RI-TATp53C9 peptide induced a stronger cell
cycle arrest at substantially lower concentrations (Figure 1C).
A single administration of the L-isomer p53C9TAT peptide
partially arrested cells for 24 h, but by 48 h cells had
reentered the cell cycle (Figure 1C). In contrast, a single dose
of the D-isomer RI-TATp53C9 peptide was sufﬁcient to
sustain a G1 arrest for greater than 7 d (Figure 1C; data not
shown).
To ascertain whether sustained arrest required the con-
tinuous presence of RI-TATp53C9 peptide, TA3/St cells were
treated with peptide or vehicle for 2 d and then replated
under mitogenic conditions in the absence of peptide.
Peptide-treated tumor cells formed less than 1% as many
colonies as vehicle-treated cells (Figure 1D). This observation
suggested that RI-TATp53C9 peptide induced a permanent
growth arrest in TA3/St cells. We therefore assayed RI-
TATp53C9 peptide-treated cells for induction of senescence,
a state of terminal arrest that can be induced by p53
activation (Roninson et al. 2002). By 6 d after peptide
addition, greater than 80% of viable TA3/St cells were
positive for acidic b-galactosidase activity (Figure 1E), the
standard marker of senescence (Roninson et al. 2002). The
treated cells also displayed other features of senescence
(Roninson et al. 2002), including increased size, increased
granularity, and a ﬂattened morphology (Figure 1E; data not
shown). These observations suggest that treatment of mam-
mary carcinoma cells with the RI-TATp53C9 peptide induces
hallmarks of p53 activation, namely a G1 cell cycle arrest
followed by induction of senescence.
We next investigated the ability of the RI-TATp53C9
peptide to transcriptionally activate p53-responsive genes.
We transiently transfected p53 null human H1299 lung
carcinoma cells with p53-dependent luciferase reporter
plasmid (PG13-Luc) and either wild-type p53 expression
plasmid or empty vector. The use of p53 null cells allows for
negative controls that are not possible in cells expressing
endogenous p53. As expected, we observed a p53-dependent
induction of luciferase activity in cells transfected with p53
expression vector (Figure 2A). However, RI-TATp53C9 pep-
tide treatment of cells transfected with p53 expression vector
resulted in a signiﬁcant increase in p53-dependent luciferase
activity (Figure 2A, left). Consistent with observations in TA3/
St cells (see Figure 1B and 1C), mutant peptide and L-isomer
p53C9TAT displayed substantially reduced potency in this
assay when compared to RI-TATp53C9 peptide (data not
shown). Importantly, RI-TATp53C9 peptide treatment of cells
transfected with empty vector and luciferase plasmids caused
no increase in p53 target promoter activity (Figure 2A). In
addition, RI-TATp53C9 peptide activated p53-dependent
transcription in SW480 colon carcinoma cells expressing a
p53 DNA contact mutant (R273H) and in H1299 p53 null
colon carcinoma cells transfected with a p53 DNA contact
mutant (R248Q and R273H) (Figure 2A, right), though to a
lesser extent than in the presence of wild-type p53 (Figure 2A,
left). These observations show that RI-TATp53C9 peptide
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retains the ability to speciﬁcally activate p53-dependent gene
transcription.
To conﬁrm that the RI-TATp53C9 peptide inhibited tumor
cell proliferation in a p53-dependent fashion, we compared
parental p53þ/þ HCT116 colorectal carcinoma cells to
HCT116 cells that were rendered p53-deﬁcient at both loci
by targeted genetic recombination (Bunz et al. 1998). Treat-
ment of wild-type p53 HCT116 cells with RI-TATp53C9
peptide inhibited cell proliferation in a dose-dependent
manner (Figure 2B). In contrast, RI-TATp53C9 peptide
treatment of p53-deﬁcient HCT116 cells did not signiﬁcantly
alter the number of viable cells. p53-deﬁcient human H1299
lung adenocarcinoma cells also failed to respond to the RI-
TATp53C9 peptide (Figure 2C), further conﬁrming the
speciﬁcity of peptide action. RI-TATp53C9 peptide inhibited
proliferation of TA3/St cells (p53þ/þ) and human Namalwa
lymphoma cells that express a p53 hotspot DNA contact
mutant (R248Q) (Figure 2C). In contrast, RI-TATp53C9
peptide did not alter the proliferation of normal human
foreskin ﬁbroblasts containing wild-type p53 (Figure 2C).
These results are consistent with previous observations that
certain p53 contact mutations are susceptible to p53C9
peptide activation and that the p53C9 peptide induces
apoptosis in tumor cells, but not normal cells (Selivanova et
al. 1997, 1998; Kim et al. 1999). Taken together, these
observations demonstrate both the p53 and tumor depend-
ency of the RI-TATp53C9 peptide.
Systemic Delivery of RI-TATp53C9 Peptide Inhibits Solid
Tumor Growth
We (Schwarze et al. 1999) and others (Datta et al. 2001;
Harada et al. 2002) have previously shown that intraperito-
neal (IP) administration of TAT–fusion peptides and proteins
results in systemic delivery in animal models. Consistent with
Figure 1. RI-TATp53C9 Induces the Hall-
marks of p53 Activity in TA3/St Mammary
Carcinoma Cells
(A) Sequence of p53C9TAT peptide (L-
amino acids) and its retro-inverso ana-
logue (D-amino acids). To generate a
negative control peptide, three essential
lysine residues (Selivanova et al. 1997)
were mutated while leaving the remain-
ing peptide sequence intact.
(B) Induction of G1 arrest in TA3/St cells
by wild-type RI-TATp53C9, but not
mutant peptide, 24 h after peptide
addition.
(C) Dose-dependent induction of G1
arrest by RI-TATp53C9 (open square)
(D-amino acids) and the less potent
p53C9TAT (open circle) (L-amino acids)
but not mutant (open triangle) peptide
at 24 h (left) and 48 h (right) after single
treatment.
(D) Induction of a permanent growth
arrest in TA3/St cells by RI-TATp53C9.
Cells were treated with RI-TATp53C9
peptide or vehicle for 2 d, replated, and
allowed to proliferate in the presence of
serum for 10 d. Colonies were then
stained with methylene blue.
(E) Induction of a senescence-like phe-
notype in TA3/St cells by RI-TATp53C9.
Cells were treated with RI-TATp53C9
peptide and stained for acidic b-galacto-
sidase activity.
DOI: 10.1371/journal.pbio.0020036.g001
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these observations, IP injection of a biotinylated RI-
TATp53C9 peptide into mice harboring subcutaneous tumors
resulted in distribution of the peptide throughout the tumor
(Figure 3A).
We next tested the ability of IP administration of RI-
TATp53C9 peptide to inhibit the growth of distant solid
tumors in immune competent mice. Subcutaneous tumors in
mice receiving either vehicle or mutant peptide grew rapidly,
reaching an average volume of nearly 600 mm3 by the end of
treatment (Figure 3B). In contrast, tumors in mice treated
with wild-type RI-TATp53C9 peptide were signiﬁcantly
retarded in growth and reached a ﬁnal mean volume less
than 50% that of tumors in the control-treated mice (p =
0.01) (Figure 3B). These observations demonstrate that
systemic delivery of RI-TATp53C9 peptide in immune
competent mice can signiﬁcantly inhibit the growth of an
aggressively proliferating solid tumor at a distant site.
RI-TATp53C9 Peptide Treatment of Terminal Peritoneal
Carcinomatosis
Because of their encapsulation and ectopic site of growth,
subcutaneous tumors fail to replicate many of the features of
terminal human cancer. We therefore tested the efﬁcacy of
RI-TATp53C9 peptide in a terminal peritoneal carcinoma-
tosis mouse model that more closely resembles metastatic
human disease. TA3/St carcinoma cells inoculated into the
peritoneum of immune competent, syngeneic A/Jax (A/J) mice
proliferated in a rapid logarithmic fashion, doubling in 24 h
and increasing their numbers 100-fold 5 d postinoculation
(Nagy et al. 1993). This aggressive, terminal peritoneal
carcinomatosis model of human disease has been used
extensively to study the pathophysiology of peritoneal tumor
growth (Nagy et al. 1993, 1995).
We assayed the ability of the RI-TATp53C9 peptide to alter
the tumor burden and increase the longevity of mice
harboring TA3/St peritoneal carcinomatosis. Vehicle-treated
mice rapidly succumbed to peritoneal tumor burden with a
mean survival time of 11 d (Figure 4A). Mice treated with
control mutant peptide succumbed to their tumor burden
with similar kinetics and a mean survival time of 10 d (Figure
4A). In contrast, peritoneal tumor-bearing mice treated with
wild-type RI-TATp53C9 peptide lived on average more than
70 d after tumor inoculation (Figure 4A), a greater than 6-
fold increase in lifespan over mutant peptide- or vehicle-
treated mice (p , 106). These observations demonstrate the
ability of transducible peptides to signiﬁcantly extend
survival in a mouse model of terminal peritoneal carcinoma-
tosis.
We next investigated the biological consequences of
peptide treatment to tumor cells in vivo. Peritoneal-TA3/St
tumor-bearing mice were given daily injections of wild-type
RI-TATp53C9 peptide or vehicle control. Mice were sacriﬁced
3 d after tumor cell inoculation for assessment of tumor
Figure 2. RI-TATp53C9 Peptide Activates
p53-Dependent Transcription and Inhibits
Tumor Cells Expressing p53
(A, left) Induction of transcription from
a p53-dependent promoter by RI-
TATp53C9 only when p53 protein is
expressed. H1299 cells (p53/) were
cotransfected with p53-responsive re-
porter (PG13-Luc) and either empty
vector or p53 expression vector. De-
picted are mean and standard deviation
of triplicate results that are representa-
tive of multiple experiments.
(A, right) RI-TATp53C9 peptide activates
p53-dependent transcription in cells
expressing DNA contact mutant p53.
SW480 cells containing a DNA contact
mutant (R273H) p53 were transfected
with p53-dependent reporter (PG13-
Luc). H1299 cells (p53/) were co-trans-
fected with PG13-Luc and either R248Q
or R273H mutant p53 expression vector.
RI-TATp53C9 was added to cells, and
promoter activity was assessed 24 h later.
(B) Inhibition of tumor cell proliferation
in a p53-dependent manner by RI-
TATp53C9. Increasing concentrations
of peptide were added to HCT 116
cells (p53þ/þ) and their p53/ isogenic
derivatives. After 2 d, the number of
viable cells was assessed by Trypan blue
exclusion and normalized to the number
of viable untreated cells. Mean and
standard deviation of multiple experi-
ments are depicted.
(C) Inhibition of the proliferation of
tumor cells expressing wild-type or
mutant p53, but not p53/ tumor cells
or nontransformed human ﬁbroblasts.
Cell viability was assessed as in (B). Mean
and standard deviation of multiple ex-
periments are depicted.
DOI: 10.1371/journal.pbio.0020036.g002
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burden. Vehicle-treated mice contained a signiﬁcant tumor
burden of recoverable dividing TA3/St tumor cells (Figure
4B). In contrast, mice treated with wild-type RI-TATp53C9
peptide showed a dramatic reduction in tumor cell number,
suggesting that RI-TATp53C9 peptide treatment extended
survival by directly inhibiting overall tumor proliferation.
Consistent with cell culture studies, cell cycle analysis of
tumor cells from peptide-treated mice showed an increase in
G1 phase of the cell cycle (data not shown).
RI-TATp53C9 Peptide Treatment of Terminal Peritoneal
Lymphoma
To broaden these results, we also tested the efﬁcacy of the
RI-TATp53C9 peptide in a mouse model of aggressive,
disseminated peritoneal lymphoma. Wild-type RI-TATp53C9
peptide, but not mutant peptide, induced G1 phase accumu-
lation and substantial apoptosis in Namalwa human lympho-
ma cells (Figure 5A). When injected IP into SCID (severe
combined immune deﬁciency) mice, Namalwa cells prolifer-
ate in the peritoneum and disseminate to other locations
(e.g., spleen, lymph nodes, and blood [de Menezes et al. 1998]),
modeling human B-cell lymphoma (Bertolini et al. 2000).
Mice harboring peritoneal lymphoma succumbed to tumor
burden with similar kinetics when treated with either vehicle
or mutant peptide, with a mean survival time of 35 d and 33 d,
respectively (Figure 5B). In contrast, wild-type RI-TATp53C9
peptide treatment resulted in 50% long-term survival (p ,
0.0007) (Figure 5B), with six of 12 treated mice still healthy at
more than 200 d after tumor cell injection. Taken together,
these observations demonstrate that in models of terminal
metastatic human disease, transducible p53-activating pep-
tides can modulate tumor biology in vivo, resulting in
signiﬁcantly decreased tumor burden, increased lifespan,
and long-term disease-free survival.
The subset of RI-TATp53C9 peptide-treated animals that
succumbed to peritoneal carcinomatosis could have failed
treatment either because of the emergence of peptide-
resistant tumor cells or because of insufﬁcient treatment
Figure 3. Solid Tumor Growth Is Inhibited by Systemic RI-TATp53C9
Peptide Administration
(A) Delivery of RI-TATp53C9-biotin to subcutaneous TA3/St tumors
after IP administration to immune competent A/J mice.
(B) Reduction of solid TA3/St tumor growth in immune competent
mice as a result of systemic administration of RI-TATp53C9. TA3/St
cells were injected subcutaneously into A/J mice and allowed to grow
to an average size of approximately 100 mm3. Mice were then sorted
into treatment groups that received eight daily injections of vehicle
(open circle) (n = 17), 650 lg of mutant peptide (open diamond) (n =
7), or 650 lg of wild-type RI-TATp53C9 peptide (open triangle) (n =
11). Final mean tumor volumes were 573 mm3 for vehicle-treated
mice, 550 mm3 for mice treated with mutant peptide, and 268 mm3
for the wild-type RI-TATp53C9 peptide group.
DOI: 10.1371/journal.pbio.0020036.g003
Figure 4. RI-TATp53C9 Treatment Extends Survival of Mice Harboring
Terminal Peritoneal Carcinomatosis
(A) A 6-fold increase in survival of A/J immune-competent mice
harboring lethal TA3/St mammary peritoneal carcinomatosis burden
after RI-TATp53C9 peptide treatment. A/J mice were given IP
injections of TA3/St cells, and cells were allowed to double in
number (approximately 24 h). Peritoneal tumor-bearing mice were
then treated once a day for 12 consecutive days with vehicle (n = 15),
600 lg of wild-type RI-TATp53C9 (n = 10), or 600 lg of mutant
peptide (n = 10). Mean survival duration was 11 d for vehicle-treated
mice, 10 d for mice receiving mutant peptide, and greater than 70 d
for the group receiving wild-type RI-TATp53C9 peptide.
(B) Reduction of tumor cell number in vivo by RI-TATp53C9
treatment. Mice were injected with TA3/St tumor cells and treated
with wild-type peptide as in (A). Three days after tumor cell injection,
cells were ﬂushed from the peritoneal cavity and serially diluted in 6-
well plates. Growth of colonies was then assessed by methylene blue
staining and used to measure the number of viable tumor cells
present in the peritoneum after treatment with vehicle or wild-type
peptide.
DOI: 10.1371/journal.pbio.0020036.g004
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duration. To distinguish between these two possibilities, we
isolated TA3/St and Namalwa cells from animals that failed
treatment. In both cases, the cells readily proliferated in
culture under the same conditions as the parental cell
population (data not shown). RI-TATp53C9 peptide treat-
ment of reconstituted TA3/St cells induced a G1 arrest similar
in extent to that of the parental cell line (Figure 6A). RI-
TATp53C9 peptide treatment of reconstituted Namalwa cells
also inhibited the viability of both parental and reconstituted
cells to the same degree (Figure 6B). These observations
demonstrate that treatment failure is not due to acquisition
of RI-TATp53C9 peptide resistance and suggests that an
extended treatment protocol (greater than 12 d) may lead to a
further enhancement of survival in these preclinical cancer
models.
Discussion
Advanced-stage peritoneal carcinomatosis and dissemi-
nated peritoneal lymphomas are often resistant to current
chemotherapy treatment (Parsons et al. 1996), and new
strategies for treating these diseases are clearly needed. The
need to develop different therapeutic modalities to restore
tumor suppressor function is acutely illustrated by the
current limitations of viral/DNA-based strategies for deliver-
ing tumor suppressor genes to cancer cells in patients
(McCormick 2001). Here we show that macromolecular
biological cargo can be delivered via TAT-mediated trans-
duction in order to modulate tumor biology in vivo.
Speciﬁcally, we ﬁnd that delivery of a transducible p53-
activating peptide in sensitive tumor cells inhibits solid
tumor growth in vivo (see Figure 3) and dramatically extends
survival (greater than 6-fold), yielding disease-free animals in
terminal peritoneal cancer models of human metastatic
disease (see Figures 4 and 5).
The vast majority of tumors express either wild-type p53
Figure 5. RI-TATp53C9 Treatment Leads to 50% Long-Term Survival of
Mice Bearing Terminal Peritoneal Lymphoma
(A) Treatment of human Namalwa B-cell lymphoma cells with RI-
TATp53C9 peptide induces apoptosis. Cells were treated with wild-
type or mutant peptide, and DNA content was analyzed by ﬂow
cytometry 24 h after peptide addition.
(B) Long-term survival of SCID mice harboring lethal peritoneal
Namalwa lymphoma tumor burden after RI-TATp53C9 peptide
treatment. Namalwa lymphoma cells were IP injected into SCID
mice and allowed to proliferate for 48 h. Mice were then injected 16
times over 20 d with vehicle control (n = 16), 900 lg of wild-type RI-
TATp53C9 peptide (n = 12), or 900 lg of mutant peptide (n = 6).
Mean survival duration was 35 d for vehicle-treated mice and 33 d for
mice receiving mutant peptide, whereas 50% of mice treated with
wild-type RI-TATp53C9 peptide remained healthy at 150 d after
tumor cell injection.
DOI: 10.1371/journal.pbio.0020036.g005
Figure 6. Tumor-Reconstituted Cells from Treated Mice Remain Sensitive
to RI-TATp53C9 Peptide-Induced G1 Arrest or Apoptosis in Culture
(A) TA3/St cells were recovered from an A/J mouse treated with RI-
TATp53C9 peptide and grown in DMEM/10% FBS. Recovered cells
were treated with increasing concentrations of RI-TATp53C9 peptide
and then analyzed for DNA content by ﬂow cytometry 24 h later.
(B) Namalwa cells were recovered from a SCID mouse treated with RI-
TATp53C9 peptide and grown in RPMI plus 10% FBS. Recovered
cells were treated with increasing concentrations of RI-TATp53C9
peptide. After 2 d, the number of viable cells was assessed by Trypan
blue exclusion and normalized to the number of viable untreated
cells. Mean and standard deviation of multiple experiments are
depicted.
DOI: 10.1371/journal.pbio.0020036.g006
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protein or a full-length p53 point mutant (Vousden and Lu
2002). This observation has led to the hypothesis that
reactivation of endogenous p53 protein will be a useful
means of treating cancer. The data presented here provide
evidence for this hypothesis by showing that TAT-mediated
delivery of a p53-activating peptide in vivo is an effective
treatment for multiple preclinical cancer models. This
macromolecular approach to p53 reactivation has certain
advantages over the limited number of small molecule-based
strategies reported to reactivate mutant p53 in vivo (Foster et
al. 1999; Bykov et al. 2002). First, the RI-TATp53C9 peptide
can activate wild-type p53 in addition to several p53 contact
mutants. Second, small molecules may suffer from a lack of
speciﬁcity (Rippin et al. 2002) in comparison to larger, more
information-rich macromolecules. Finally, recent investiga-
tions into the mechanism of TAT-mediated transduction
(Richard et al. 2002; Fittipaldi et al. 2003) suggest that, unlike
small molecules, TAT-linked cargo is taken up by macro-
pinocytosis (Wadia et al. 2004) and is therefore not
susceptible to the multidrug resistance phenotype. Theoret-
ically, tumors could avoid the RI-TATp53C9 peptide action by
mutating or deleting p53; however, we did not observe
peptide resistance here (see Figure 6). Therefore, we conclude
that linking PTDs to p53C9 and to other p53-activating
peptides may be an effective therapeutic strategy applicable
to a signiﬁcant fraction of human cancers.
The work presented here provides several broad lines of
evidence for the general feasibility of applying in vivo TAT-
mediated transduction to cancer therapy. First, we ﬁnd that
inversion of the p53C9TAT peptide sequence and synthesis
with D-amino acids results in a highly stable peptide (RI-
TATp53C9) that retains both biological activity and the ability
to transduce into cells. Given the rapid degradation of L-
residue-containing peptides in vivo (Chorev and Goodman
1993), use of retro-inverso transformations with D-isomer
residues and/or other stabilizing procedures will likely be
essential for the pharmacological use of transducible pep-
tides. Second, given the history of virus-mediated gene
delivery, the necessity of validating new therapeutic ap-
proaches to systemic disease in the context of an intact
immune system cannot be underestimated. Consequently,
here we demonstrate that TAT-mediated systemic delivery
inhibits tumor growth in immune competent animals.
Finally, most studies on anticancer transduction peptides
have relied primarily on the use of solid, subcutaneous tumor
growth as a measure of efﬁcacy (Datta et al. 2001; Harada et
al. 2002). Although informative, such studies are inherently
limited by the minimal impact that subcutaneous tumors
have on the biology of the host and by the failure of this type
of tumor to closely mimic human disease. In contrast, the
more rigorous peritoneal carcinomatosis and peritoneal
lymphoma models used here require that therapeutic agents
be able to suppress tumors to such an extent that the
deleterious effects of the tumor on host physiology are
substantially ameliorated. This is a particularly salient point
because cancer patients generally do not succumb to the
primary tumor burden but to complications from metastatic
disease (Fidler 2003). Indeed, anticancer therapeutics are
deﬁned as clinically successful by their ability to alleviate
pathology and extend survival and not simply by their ability
to reduce tumor volume. Our work here, combined with that
of Fulda et al. (2002), demonstrates that transducible agents
can effectively treat rigorous models of terminal cancer.
Current clinical use of macromolecular biological thera-
pies is limited to agents that have an extracellular mode of
action. The preclinical data presented here demonstrate a
proof-of-concept that intracellular delivery of biologically
active macromolecular cargo by TAT-mediated transduction
can modify speciﬁc pathways in vivo and that this approach
potentially serves as a foundation for the generation of new
classes of intracellular biological therapeutics.
Materials and Methods
Cell culture and ﬂow cytometry. TA3/St (gift of W. G. Kaelin),
H1299 (gift of R. K. Brachmann), and human foreskin ﬁbroblast (M.
Haas) cells were maintained in DMEM plus 10% fetal bovine serum
(FBS) and penicillin/streptomycin (P/S). Namalwa cells (American
Type Culture Collection, Manassas, Virginia, United States) were
maintained in RPMI plus 10% FBS, P/S. HCT116 cells (gift of B.
Vogelstein) were grown in McCoy’s medium plus 10% FBS, P/S. All
cells were maintained at 378C in 5% CO2. Short-term cell viability was
assessed by counting Trypan blue-excluding cells on a hemocytom-
eter. Long-term cell viability was assessed by colony formation assay.
After serial dilution and 10 d of culture, colonies were washed in PBS
and stained with 1%methylene blue. Cellular senescence was assessed
by X-Gal staining as previously described (Schwarze et al. 1999),
except for the use of PBS (pH 6.0). For cell cycle analysis, TA3/St cells
were treated with 0.25–10 lM peptide and Namalwa cells with 40 lM
peptide. DNA was stained 24 h later with 10 lg/ml propidium iodide
in 0.5% NP-40 (TA3/St cells) or Draq5 (Namalwa cells) per the
manufacturer’s instructions (Qbiogene, Carlsbad, California, United
States). DNA proﬁles were analyzed using a FACScan and CellQuest
software (Becton Dickinson, Palo Alto, California, United States).
Peptide synthesis. Peptides were synthesized by standard Fmoc
chemistry on an ABI 433A Peptide Synthesizer (Applied Biosystems,
Foster City, California, United States). Crude peptides were puriﬁed
by reverse-phase HPLC over a C18 preparatory column (Varian, Palo
Alto, California, United States). The identity of all peptides was
conﬁrmed by mass spectrometry.
Promoter activity assays. In a 96-well dish, 43104 cells were plated
per well. The next day, H1299 cells were transfected with 15 ng of TK-
Renilla (Promega, Madison, Wisconsin, United States), 200 ng of
PG13-Luc, and one of the following: 0.3 ng of empty vector, 0.3 ng of
p53 expression vector, or 1 ng mutant of p53 expression vector (gift
of R. K Brachmann). SW480 cells were transfected with 25 ng of TK-
Renilla and 250 ng of PG13-Luc reporter plasmid. Cells were all
transfected using Lipofectamine 2000 per the manufacturer’s
protocol (Invitrogen, Carlsbad, California, United States). After 5 h,
the transfection medium was removed and peptides were added to
cells. Luciferase activity was measured 24 h later with the Dual
Luciferase Reporter Assay System per the manufacturer’s instruc-
tions (Promega).
Animal tumor models. For TA3/St tumor models, 4- to 8-wk-old
immune competent A/J female mice were obtained from Jackson
Laboratory (Bar Harbor, Maine, United States). Solid TA3/St tumors
were generated by subcutaneous injection of 1.53 106 TA3/St cells in
200 ll of Hanks’ balanced salt solution (HBSS). Tumor volume was
estimated by V = (a23 b)/2, where a is the short axis and b is the long
axis of the tumor. IP TA3/St tumors were generated by injection of 2
3 106 TA3/St cells IP in 400 ll of HBSS. For the Namalwa lymphoma
tumor model, 6- to 8-wk-old CB17 SCID female mice were obtained
from Charles River Laboratory (Wilmington, Massachusetts, United
States). Then, 5 3 105 Namalwa lymphoma cells were injected IP in
400 ll of HBSS. Peptide was dissolved in water, brought to 600 ll in
PBS, and injected IP. All animal studies were approved by the
University of California, San Diego, Institutional Animal Care and
Use Committee.
Histology. Mice harboring solid TA3/St tumors were injected with
650 lg of biotinylated RI-TATp53C9 peptide and sacriﬁced 1 h
postinjection. Sections from frozen tumors were stained with
Vectastain Elite ABC Kit and DAB substrate per the manufacturer’s
instructions (Vector Laboratories, Burlingame, California, United
States).
Statistical analysis. Student’s t-test was used to determine statistical
signiﬁcance (p , 0.05) in all experiments except animal survival
experiments, in which the Wilcoxon Rank-Sum Test was performed.
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